NCT05546411 - A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

August 16, 2023

Study Completion Date

October 13, 2023

Conditions

Pancreatic CancerResectable Pancreatic CancerBorderline Resectable Pancreatic AdenocarcinomaPancreatic Adenocarcinoma

Interventions

DRUG

mFOLFIRINOX

Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion

DRUG

5-Fluorouracil (5-FU)

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

Oxaliplatin

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

Irinotecan

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

Leucovorin

Part of the FOLFIRINOX drug combination, given by intravenous infusion

DRUG

NIS793

Given by intravenous infusion

RADIATION

Chemoradiation

Combination of Chemo (Capecitabine) and Radiation Therapy

PROCEDURE

Surgery

Surgical removal of tumor

Trial Locations (2)

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston